John M Abrahams, MD, MS
Co-Founder and Board Memeber
Dr. Abrahams is Associate Professor of Neurological Surgery at New York Medical College, Westchester Medical Center, a Level 1 Trauma Center. He is also Assistant Professor at Albert Einstein College of Medicine, Montefiore Medical center. Within the practice of neurosurgery, Dr. Abrahams has a focus on intracranial surgery and brain tumors. He is the founder of the Westchester Neuroscience Research Foundation to research malignant brain tumors, stroke and spinal cord injuries. Dr. Abrahams has authored over 25 peer-reviewed articles and book chapters. He has received the Galbraith Award for Research in Cerebrovascular Surgery from the Congress of Neurological Surgeons and other awards. Dr. Abrahams is also an inventor and entrepreneur, having developed and patented devices to support the development of less invasive and tissue-sparing approaches. Along with Weiliam Chen, Dr. Abrahams is a co-founder of Endomedix.
Dr. Abrahams received a BS in Physics from LeMoyne College and a MS degree in Biomedical Engineering from Rensselaer Polytechnic Institute. He received his medical degree from New Medical College and performed his Residency in Neurosurgery at University of Pennsylvania. Dr. Abrahams completed both a Spine Fellowship and a Research Fellowship at the Hospital of the University of Pennsylvania.
Weiliam Chen, Ph.D, RPH
Co-Founder and Board Member
Weiliam Chen has 20 years of research experience in both university-based research centers and associated private research groups. He has held a number of academic appointments, including posts at University of Pennsylvania School of Medicine/Children’s Hospital of Philadelphia and New York University School of Medicine. Dr. Chen is a co-founder of Sustained Nano Systems, LLC, a preclinical stage firm using nanovector and microvector components to enhance drug delivery, where he developed early prototypes and demonstrations of efficacy. Dr. Chen also developed formulas and prototypes for Clear Solutions, a cosmetics firm acquired by Engelhard Corporation. Along with Dr. Abrahams, Dr. Chen is a co-founder of Endomedix.
Dr. Chen has been the recipient of 17 grants from the US government and other sources totaling $11.2 million, including the 8 NIH-sponsored SBIR grants awarded to date to Endomedix, with a total value of $2.8 million. Dr. Chen also serves as a grant applications reviewer for a number of national and international grant review panels including the National Institutes of Health, the Department of Defense, the Science Foundation of Ireland, UK Medical Research Council, Israel Science foundation, and Portugal Fundação para a Ciência e a Tecnologia.
Dr. Chen earned a BS in Pharmacy from the University of Wisconsin-Madison, a MS and a PH.D in Pharmaceutics from the University of Michigan-Ann Arbor, and held a post-doctoral fellowship in pediatric cardiology at the University of Michigan Medical Center.
Richard A. Olson
Richard Olson joined the Board in 2012 after 40+ year career centered on the development and commercialization of pharmaceutical and OTC products. He held senior positions in operating management, with responsibilities for domestic and international marketing, new product introductions and business development with leading firms such as Schering-Plough Healthcare Products, Fisons Corporation PLC, and Richardson-Vicks. Mr. Olson was also the founder and CEO of Creative technology Partners, a consulting and business development firm, and was an “Entrepreneur in Residence “at the Enterprise Development Center incubator at NJIT.
Mr. Olson earned a B.Sc. and a MBA degree from Cornell University.
James. R. Pastena
James (Jim) Pastena is a medical device executive with a successful track record in both larger corporations and start-up companies. He is currently CEO and Chairman of Precision Spine, Inc., a privately held spinal implant firm, and was co-founder and CEO of ElectroCore®, LLC, a leading edge neuromodulation medical device start-up working in the field of bronchoconstriction. Jim served as president of President of EBI, a unit of Biomet, which grew under his leadership from $85 million to $500 million in annual revenue and no. 4 global market share in the spinal implant market. During his tenure at EBI, he pioneered innovative sales force strategies. Jim currently sits on the Boards of several other medical products companies. Jim earned a BS in Marketing from Fairleigh Dickenson University.
Over a 30+ year career, Richard Russo has demonstrated particular strengths in new product development & commercialization, clinical research & regulatory affairs, & start-up management. Prior to joining Endomedix, Richard was President & CEO of OST Développement SA, a French subsidiary of a NASDAQ firm, Osteotech, Inc. Starting from a base of virtually no customers, OST quickly built a $24M business by restructuring the practice of bone grafting in countries in Europe, Asia & Latin America. Richard was also a seed investor & manager in Meditron Corporation which successfully developed a class III device & was acquired by Cross Medical. Prior to Meditron, he was a manager of a small public company, Electro-Biology Inc., which was acquired by Biomet. Richard has also worked at major firms such as Baxter International, C.R bard & American Sterilizer Co. in positions of progressively increasing responsibilities. Richard joined Endomedix in 2009 as President and Chief Executive Officer. Since he arrived, Richard redirected the Company from its original business model and business strategy; negotiated the cancellation of a licensing agreement with Integra Life Sciences; re-established the laboratory and the Company’s product development team; led the IP program that has produced 7 issued patents in US, Canada and Europe; and led the development of its current technology platform. In addition to his position as President and Chief Executive Officer, Richard serves on the Board of Directors. Richard earned a BA cum laude at Boston College and a MBA at Columbia Business School.